image
Mobile_image
eyebrow
For adults with relapsed classical Hodgkin lymphoma
headline

How may I benefit from ADCETRIS?

headline

Study design

content

An international, clinical study of 102 people evaluated the effectiveness and safety of ADCETRIS in patients with classical Hodgkin lymphoma that came back after stem cell transplant.

  • 102 people were assigned to receive ADCETRIS every 3 weeks for up to 16 cycles


Researchers reviewed the overall response rate (primary endpoint) and the median duration of response (secondary endpoint) at approximately 1.5 years.

headline

Overall response rate

headline2

At approximately 1.5 years, patients treated with ADCETRIS saw their classical Hodgkin lymphoma, which came back after a stem cell transplant, become reduced or undetectable.

Image
Mobile_image
headline

Median duration of response

headline2

For patients who responded to treatment with ADCETRIS, the median duration of response was 6.7 months.

image
Mobile_image
headline

What safety information should I know about ADCETRIS?

icon
headline

The most important serious safety information

content
PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY (PML): Patients treated with ADCETRIS can have a rare, serious brain infection called PML that can lead to death.

Tell your doctor immediately if you have mood or behavior changes, confusion, problems in thinking or loss of memory, changes in vision, speech, or walking, or decreased strength or weakness on one side of the body. PML may also be caused by prior treatments or diseases that weakened your immune system.

Do not take ADCETRIS with bleomycin because of possible serious side effects to the lungs. These are not the only side effects of ADCETRIS. Always tell your doctor about any side effects you experience.
icon
headline

Most common side effects while taking ADCETRIS

content
In people treated with ADCETRIS alone, the most common side effects that occurred in ≥20% of study patients were significantly low number of white blood cells (54%), nerve damage (peripheral sensory neuropathy; PN) (52%), feeling tired (49%), upper respiratory tract infection (47%), nausea (42%), diarrhea (36%), low red blood cell count (33%), fever (29%), low platelet count (28%), rash (27%), cough (25%), stomach pain (25%), and vomiting (22%).

The most common serious side effects in study patients were weakness in the hands or feet (peripheral motor neuropathy) (4%), stomach pain (3%), blood clots in the lungs (2%), inflamed lungs (2%), collapsed lung (2%), kidney infections (2%), and fever (2%).

For more information on side effects, please see the Important Safety Information at the bottom of this page and read the Important Facts about ADCETRIS, including BOXED WARNING.
headline

Tell your doctor about any side effect concerns you have

content

Don’t stop, change, or delay your ADCETRIS treatment unless directed by your doctor. Your doctor may take additional steps to help manage side effects, including:

  • Reducing your ADCETRIS dosage, or delaying your next dose, until symptoms improve
  • Stopping ADCETRIS completely if side effects are severe or do not improve


For more information about understanding side effects, download a copy of the ADCETRIS side effects guide

Icon
headline

Learn more about what you can expect before starting ADCETRIS treatment.

Content
buttons
Find out how ADCETRIS is given
headline

Glossary

content

Median: The middle number in a list of numbers.

Overall response rate: The percentage of people in a study or treatment group who have a partial response or complete response to the treatment within a certain period of time. Measuring the overall response rate is one way to see how well a new treatment works.

Stem cell transplant: A procedure in which a patient receives healthy stem cells (blood-forming cells) to replace their own stem cells that have been destroyed by certain cancer treatments.